• Bird, J., Behrens, J., Westin, J., Turesson, I., Drayson, M., Beetham, R., D'Sa, S., Soutar, R., Waage, A., Gulbrandsen, N., Gregersen, H. & Low, E. (2009) UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology, 147, 2242.
  • Bird, J., Owen, R., D'Sa, S., Snowden, J., Pratt, G., Littlewood, T., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., Morgen, G., Cavenagh, J., Low, E. & Behrens, J. (2010) Guidelines on the diagnosis and management of multiple myeloma. British Journal of Haematology, 152, 3275.
  • Bradwell, A.R., Carr-Smith, H.D., Mead, G.P., Tang, L.X., Showell, P.J., Drayson, M.T. & Drew, R. (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clinical Chemistry, 47, 673680.
  • Dingli, D., Kyle, R.A., Rajkumar, S.V., Nowakowski, G.S., Larson, D.R., Bida, J.P., Gertz, M.A., Therneau, T.M., Melton, L.J., Dispenzieri, A. & Katzmann, J.A. (2006) Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood, 108, 19791983.
  • Dispenzieri, A., Lacy, M.Q., Katzmann, J.A., Rajkumar, S.V., Abraham, R.S., Hayman, S.R., Kumar, S.K., Clark, R., Kyle, R.A., Litzow, M.R., Inwards, D.J., Ansell, S.M., Micallef, I.M., Porrata, L.F., Elliott, M.A., Johnston, P.B., Greipp, P.R., Witzig, T.E., Zeldenrust, S.R., Russell, S.J., Gastineau, D. & Gertz, M.A. (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 107, 33783383.
  • Dispenzieri, A., Kyle, R.A., Katzmann, J.A., Therneau, T.M., Larson, D., Benson, J., Clark, R.J., Melton, L.J., Gertz, M.A., Kumar, S.K., Fonseca, R., Jelinek, D.F. & Rajkumar, S.V. (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood, 111, 785789.
  • Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J.S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., Dimopoulos, M., Comenzo, R., Einsele, H., Barlogie, B., Anderson, K., Gertz, M., Harousseau, J.L., Attal, M., Tosi, P., Sonneveld, P., Boccadoro, M., Morgan, G., Richardson, P., Sezer, O., Mateos, M V., Cavo, M., Joshua, D., Turesson, I., Chen, W., Shimizu, K., Powles, R., Rajkumar, S V. & Durie, B G M (2009) International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia, 23, 215224.
  • Drayson, M., Tang, L.X., Drew, R., Mead, G.P., Carr-Smith, H.D. & Bradwell, A.R. (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood, 97, 29002902.
  • Drayson, M., Begum, G., Basu, S., Makkuni, S., Dunn, J., Barth, N. & Child, J.A. (2006) Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood, 108, 20132019.
  • Filippi, R.D., Laccarino, G., Frigeri, F., Francia, R.D., Amoroso, B., Marchei, A. & Pinto, A. (2008) The presence of serum free-immunoglobulin light chains and abnormal κ/λ ratios is a frequent finding in patients with Hodgkin's and B-cell non-Hodgkin's lymphoma. Hematology Meeting Reports 2, 2, 18a.
  • Itzykson, R., Le Garff-Tavernier, M., Katsahian, S., Diemert, M.-C., Musset, L. & Leblond, V. (2008) Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. Haematologica, 93, 793794.
  • Kang, S.-Y., Suh, J.-T., Lee, H.-J., Yoon, H.-J. & Lee, W.-I. (2005) Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Annals of Hematology, 84, 588593.
  • Katzmann, J.A., Clark, R.J., Abraham, R.S., Bryant, S., Lymp, J.F., Bradwell, A.R. & Kyle, R.A. (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clinical Chemistry, 48, 14371444.
  • Keren, D.F. (1999) Procedures for the evaluation of Monoclonal Immunoglobulins. Archives of Pathology and Laboratory Medicine, 123, 126132.
  • Kyrtsonis, M.-C., Vassilakopoulos, T.P., Kafasi, N., Sachanas, S., Tzenou, T., Papadogiannis, A., Galanis, Z., Kalpadakis, C., Dimou, M., Kyriakou, E., Angelopoulou, M.K., Dimopoulou, M.N., Siakantaris, M.P., Dimitriadou, E.M., Kokoris, S.I., Panayiotidis, P. & Pangalis, G. A. (2007) Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. British Journal of Haematology, 137, 240243.
  • Landgren, O., Goedert, J.J., Rabkin, C.S., Wilson, W.H., Dunleavy, K., Kyle, R.A., Katzmann, J.A., Rajkumar, S.V. & Engels, E.A. (2010) Circulating serum free light chains as predictive markers of AIDS-related lymphoma. Journal of Clinical Oncology, 28, 773779.
  • Martin, W., Abraham, R., Shanafelt, T., Clark, R.J., Bone, N., Geyer, S.M., Katzmann, J. A., Bradwell, A., Kay, N.E. & Witzig, T.E. (2007) Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Translational Research, 149, 231235.
  • Maurer, M.J., Micallef, I.N.M., Cerhan, J.R., Katzmann, J.A., Link, B.K., Colgan, J.P., Habermann, T.M., Inwards, D.J., Markovic, S.N., Ansell, S.M., Porrata, L.F., Johnston, P.B., Nowakowski, G.S., Thompson, C.A., Gupta, M., Syrbu, S.I., Kurtin, P.J., Macon, W.R., Nikcevich, D.A. & Witzig, T.E. (2011a) Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large b-cell lymphoma. Journal of Clinical Oncology, 29, 16201626.
  • Maurer, M.J., Cerhan, J.R., Katzmann, J.A., Link, B.K., Allmer, C., Zent, C.S., Call, T.G., Rabe, K.G., Hanson, C.A., Kay, N.E., Slager, S.L., Witzig, T.E. & Shanafelt, T.D. (2011b) Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood, 118, 28212826.
  • Pérez-Galán, P., Mora-Jensen, H., Weniger, M.A., Shaffer, A.L., Rizzatti, E.G., Chapman, C.M., Mo, C.C., Stennett, L.S., Rader, C., Liu, P., Raghavachari, N., Stetler-Stevenson, M., Yuan, C., Pittaluga, S., Maric, I., Dunleavy, K.M., Wilson, W.H., Staudt, L.M. & Wiestner, A. (2011) Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood, 117, 542552.
  • Pinto, A., De Filippi, R., Iaccarino, G., Di Francia, R., Distinto, M., Frigeri, F., Russo, F., Marchei, A. & Amoroso, B. (2008) Abnormalities in serum free-immunoglobulin light chains show a high and differential frequency among who subtypes of b-cell non-hodgkin's lymphoma (nhl) and may turn of value for therapeutic monitoring: a study of 354 newly diagnosed patients. Blood, 112, 2813.
  • Pinto, A., Iaccarino, G., Russo, F., Amoroso, B., Morelli, E., Riemma, C. & De Filippi, R. (2010) Clinical and biological relevance of serum free light chains (sFLC) assessment in patients with Hodgkin's lymphoma. Hematology Reports, 2, p15.
  • Pratt, G., Harding, S., Holder, R., Fegan, C., Pepper, C., Oscier, D., Gardiner, A., Bradwell, A.R. & Mead, G. (2009) Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 144, 217222.
  • Pratt, G., Young, P., Levoguer, A., Pepper, C., Fegan, C., Oscier, D., Mead, G. & Harding, S. (2011) Prognostic value of elevated polyclonal serumfree light chains in Stage A chronic lymphocytic leukaemia patients. Annals of Oncology, 22, abstr 260.
  • Swerdlow, S., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. International Agency for Research on Cancer (IARC), Lyon, France.
  • Yegin, Z.A., Ozkurt, Z.N. & Yağci, M. (2010) Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukemia. European Journal of Haematology, 84, 406411.